Latest Breaking News On - Gloria biosciences - Page 1 : comparemela.com

Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers

Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesFoster cityYelenay janjigianGilead sciencesArcus biosciences incGuangzhou gloria biosciences coGilead sciences incX twitter gilead sciencesExchange commissionAmerican society of clinical oncologyMemorial sloan kettering cancer centerArcus biosciencesAmerican societyClinical oncologyPlenary seriesRapid abstract updates

BioLineRx Ltd (NASDAQ:BLRX) Q1 2024 Earnings Call Transcript

Operator: Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx First Quarter 2024 Financial Results Conference Call. All participants are presently in a listen-only mode.

United statesJohn vandermostenJohn laceyGloria biosciencesPhil serlinElla soraniJoe pantginisAmerican society for apheresis annual meetingBiolinerx ltdCorporate communicationsWashington universityColumbia universityOutcomes researchExchange commissionInternational society for pharmacoeconomicsAmerican society of clinical oncology

BioLineRx : Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER .

United statesIsrael generalPhilip serlinTwitterand linkedinPhilipa serlinGloria biosciencesMoran meirJohn laceyGloria bioscienceExchange commission onMedicaid servicesLifesci advisorsWashington university in stInternational society for pharmacoeconomicsOutcomes research onAmerican society of clinical oncology

Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024

Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United arab emiratesUnited statesFoster citySanta monicaMato grosso do sulDomvanalimab domBrexucabtagene autoleucelAxicabtagene ciloleucelSacituzumab govitecanBig ten cancer research consortium studyGilead sciences incGilead sciencesEuropean unionDana farber cancer instituteGilead public affairsGuangzhou gloria biosciences co

GILEAD AND KITE ONCOLOGY TO HIGHLIGHT BROAD AND DIVERSE ONCOLOGY PORTFOLIO AT ASCO 2024

GILEAD AND KITE ONCOLOGY TO HIGHLIGHT BROAD AND DIVERSE ONCOLOGY PORTFOLIO AT ASCO 2024
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.

Foster cityUnited statesUnited kingdomSanta monicaBrexucabtagene autoleucelAxicabtagene ciloleucelSacituzumab govitecanSacituzumab govitecan hziyEuropean medicines agencyGilead companySmall cell lung cancer development program dataBig ten cancer research consortium studyGuangzhou gloria biosciences coGilead sciences incAmerican society of clinical oncologyEuropean commission